| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Net revenue | ||||||
1,626,373 | 1,662,991 | 1,033,654 | 1,018,225 | |||
Cost of goods sold | ||||||
1,147,214 | 938,773 | 507,476 | 420,770 | |||
Cost of goods sold impairment charges | ||||||
126,162 | 7,815 | 0 | - | |||
Gross profit | ||||||
352,997 | 716,403 | 526,178 | 597,455 | |||
Selling, general and administrative | ||||||
289,598 | 227,846 | 109,046 | 118,757 | |||
Research and development | ||||||
188,049 | 194,190 | 171,420 | 179,019 | |||
In-process research and development impairment charges | ||||||
46,619 | 39,259 | 0 | 0 | |||
Intellectual property legal development expenses | ||||||
14,238 | 16,261 | 20,518 | 25,728 | |||
Acquisition, transaction-related and integration expenses | ||||||
16,388 | 221,818 | 9,403 | 70 | |||
Charges related to legal matters | ||||||
-12,442 | 19,711 | 29,312 | 11,000 | |||
Restructuring and other charges | ||||||
34,345 | 56,413 | 0 | 0 | |||
Operating income (loss) | ||||||
-248,682 | -19,673 | 245,103 | 284,881 | |||
Other (expense) income: | ||||||
Interest expense, net | ||||||
-168,205 | -143,571 | -71,061 | -55,283 | |||
Foreign exchange loss, net | ||||||
-4,962 | -19,701 | 29,092 | -14,108 | |||
Loss on extinguishment of debt | ||||||
0 | -20,000 | -2,532 | 0 | |||
Gain on sale of international business | ||||||
7,258 | -2,958 | -29,232 | 0 | |||
Gain from reduction of tax receivable agreement liability | ||||||
192,884 | 1,665 | 0 | - | |||
Other income, net | ||||||
1,465 | 1,183 | -47 | -669 | |||
Total other expense, net | ||||||
28,440 | -183,049 | -73,780 | -70,060 | |||
Income (loss) before income taxes | ||||||
-220,242 | -202,722 | 171,323 | 214,821 | |||
Benefit from income taxes | ||||||
383,331 | -1,419 | 1,998 | 5,395 | |||
Net income (loss) | ||||||
-603,573 | -201,303 | 169,325 | 209,426 | |||
Less: Net loss (income) attributable to Amneal Pharmaceuticals LLC pre-Combination | ||||||
0 | -148,806 | 167,648 | 207,378 | |||
Less: Net (income) loss attributable to non-controlling interests | ||||||
-241,656 | -32,753 | 1,677 | 2,048 | |||
Net income (loss) attributable to Amneal Pharmaceuticals, Inc. | ||||||
-361,917 | -19,744 | 0 | 0 | |||
Accretion of redeemable non-controlling interest | ||||||
0 | 1,176 | 0 | 0 | |||
Net loss attributable to Amneal Pharmaceuticals, Inc. | ||||||
-361,917 | -20,920 | 0 | 0 | |||
Net income (loss) per share attributable to Amneal Pharmaceuticals, Inc.'s common stockholders: | ||||||
Class A and Class B-1 basic and diluted | ||||||
-2.74 | -0.16 | - | - | |||
Class A and Class B-1 basic and diluted | ||||||
132,106 | 127,252 | - | - | |||